ist da eine dividende is aussicht?
Seite 1 von 1 Neuester Beitrag: 14.05.13 14:45 | ||||
Eröffnet am: | 11.09.12 18:10 | von: pennystocktr. | Anzahl Beiträge: | 25 |
Neuester Beitrag: | 14.05.13 14:45 | von: reza66 | Leser gesamt: | 7.290 |
Forum: | Hot-Stocks | Leser heute: | 8 | |
Bewertet mit: | ||||
also der vertrag ist noch nicht unterschrieben aber die planen eine dividende falls das geschäft mit dem käufer zustande kommt oder wie?
und wenn der käufer alles abblässt dann gibs nix ? ist wohl eher ein zock in der aktie eine wette darauf das der deal zustande kommt meiner meinung nach wer hier heute aktien gekauft hat.
vielleicht hab ichs auch falsch vertsanden vielleicht weis jemand besser bescheid?
16:40 24.09.12
PR Newswire
JERUSALEM, September 24, 2012
JERUSALEM, September 24, 2012 /PRNewswire/ --
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company's common stock became eligible for trading on the Borse Berlin, or the Berlin Stock Exchange, under the symbol "MS1" and the German security number (WKN) "A1JPAQ".
The Berlin Stock Exchange has secondary stock listings for over 6,000 U.S. securities that are listed on such exchanges as the NYSE, NASDAQ, AMEX or quoted on the OTC Bulletin Board.
"Trading shares on the Berlin exchange provides Medisafe 1 Technologies with increased exposure to the European capital markets," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "We are hopeful that access to additional investment capital can increase the company's capabilities to further develop and market our proprietary, life-saving devices."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact:
Jacob Elhadad CEO
+972-524440000
Jacob.elhadad10@gmail.com
SOURCE Medisafe 1 Technologies Corp.
Quelle: PR Newswire
nur meine meinung...
Update to Medisafe 1 Technologies Corp.SHAREHOLDERS: Due Diligence Complete Prior to Closing $7MM Perpetual License Sale
14:35 24.10.12
PR Newswire
JERUSALEM, October 24, 2012
JERUSALEM, October 24, 2012 /PRNewswire/ --
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that due diligence by both parties to the sale has been successfully completed, and the sale is expected to be finalized and initiated by November 5 2012.
The agreement will transfer rights for the full commercialization, marketing and distribution of its patented medicinal locking mechanism and bar-code matching system to a third party. Terms of the sale include a $7MM payment to Medisafe 1 Technologies.
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact:
Jacob Elhadad, CEO
+972-524440000
Jacob.elhadad10@gmail.com
bleibt also spannend hier...schau ma mal
http://ih.advfn.com/p.php?pid=nmona&article=55828982
http://ih.advfn.com/p.php?pid=nmona&article=558289
na da kann man doch mal gespannt sein
Medisafe 1 Technologies erwirtschaftet einen operativen Gewinn von rund $ 2M in das vierte Quartal des Jahres 2012.
Quelle: http://finance.yahoo.com/news/medisafe
Wenn ich mir den Jahreschart so ansehe, wird der Kurs aus charttechnischer Sicht in paar Monaten bei 0.015 US$ stehen. Sieht nach einem schönen "W" aus.
Ist nur meine Meinung und keine Kaufempfehlung.
Auch das sollte man beachten, deswegen sehen wir bald Cent-Beträge bei MFTH:
finance.yahoo.com/news/medisafe-1-technologies-signs-7mm-140000940.html
Meiner Meinung nach startet MFTH morgen auf die 0.0045/0.0050 US$.
Charttechnisch sieht es jedenfalls danach aus...
Wer heute nicht einsteigt, wird wohl nächte Woche nur noch hinterher rennen. Umsatz steigt,2 Mio.$ Gewinn im 4. Quartal 2012 und die MK liegt immer noch unter 2 Mio. $.
aktuell 0.0034 $
Kursziel 0.015 $
Nur meine Meinung.
Das Unternehmen plant eine einmalige Sonderdividende an alle bestehenden Aktionären im Rahmen einer unbefristeten Lizenzvereinbarung mit SAFECODE DRUG TECHNOLOGIES CORP.
Quelle Kaufempfehlung: http://www.nismagazine.com